Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

<p>Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns with ongoing results from investigator-sponsored trial at Fred Hutch that show ongoing complete remission for more than three years Update on data presented at 5th iwCAR-T, Scottsdale, AZ Safety […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/mustang-bio-announces-first-data-from-ongoing-multicenter-phase-1-2-clinical-trial-evaluating-mb-106-car-t-cell-therapy/">Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>